2006, Blood Pressure, DEA and Patients

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2006

Blood Pressure

DEA

Patients

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

JULY 12, 2019

Side effects were very prevalent in 79% of all patients taking a refined CBD product, some of which were severe like thrombocytopenia and transaminase elevations in the liver. Review: During an open-label trial of pure CBD with Lennox-Gastaut and Dravet patients, 79% of all patients reported side effects.

Extraction

Extraction Pharmaceutical CBD Epilepsy

AAFP ( American Academy of Family Physicians) Releases Marijuana, Cannabinoids Position Paper

Cannabis Law Report

SEPTEMBER 23, 2019

Marijuana and related substance misuse are complex issues impacting family medicine, patient health, and public health. Barriers to facilitating both clinical and public health research regarding marijuana is detrimental to treating patients and the health of the public. Executive Summary. Relevant AAFP Policy. Call to Action.

Cannabinoids

Cannabinoids Marijuana Research and Development Access

Medical Cannabis Brief

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

AAFP ( American Academy of Family Physicians) Releases Marijuana, Cannabinoids Position Paper

Stay Connected